Chronic hepatitis C is a common infection that is a major cause of chronic liver disease, liver failure, and hepatocellular carcinoma (HCC), and it is the leading indication for liver transplantation in the Western world. Prior to 2011, the combination of pegylated interferon and ribavirin was the gold standard of therapy for the treatment of chronic hepatitis C. Since 2014, several therapies have been approved to treat hepatitis C offering patients new options for treating the chronic illness.

Date of review: December 2014

For questions, contact info@icer.org.

Interventions of interest:

  • Simeprevir (Olysio®, Janssen Products, LP) + sofosbuvir (Sovaldi®, Gilead Sciences, Inc.)
  • Ledipasvir/sofosbuvir (Harvoni®, Gilead Sciences, Inc.)
  • Daclatasvir (Daklinza™, Bristol-Myers Squibb Company) + sofosbuvir (Sovaldi®, Gilead Sciences, Inc.)
  • Paritaprevir/ritonavir/ombitasvir + dasabuvir with ribavirin (Viekira Pak™, AbbVie, Inc.)
  • Simeprevir (Olysio®, Janssen Products, LP)+ pegylated interferon and ribavirin
  • Sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) + ribavirin
  • Sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) + pegylated interferon and ribavirin

Final Documents

Below you will find the final documents from the assessments review process: